CA2304376A1 - Construction d'adn pour l'expression d'un facteur de coagulation du sang a specificite tissulaire - Google Patents

Construction d'adn pour l'expression d'un facteur de coagulation du sang a specificite tissulaire Download PDF

Info

Publication number
CA2304376A1
CA2304376A1 CA002304376A CA2304376A CA2304376A1 CA 2304376 A1 CA2304376 A1 CA 2304376A1 CA 002304376 A CA002304376 A CA 002304376A CA 2304376 A CA2304376 A CA 2304376A CA 2304376 A1 CA2304376 A1 CA 2304376A1
Authority
CA
Canada
Prior art keywords
dna
construct
factor
blood coagulation
coagulation factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002304376A
Other languages
English (en)
Other versions
CA2304376C (fr
Inventor
Claude Negrier
Marie Helene Rodriguez
Nathalie Enjolras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
Aventis Behring GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Behring GmbH filed Critical Aventis Behring GmbH
Publication of CA2304376A1 publication Critical patent/CA2304376A1/fr
Application granted granted Critical
Publication of CA2304376C publication Critical patent/CA2304376C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2304376A 1999-04-27 2000-04-28 Construction d'adn pour l'expression d'un facteur de coagulation du sang a specificite tissulaire Expired - Fee Related CA2304376C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99107397A EP1048736A1 (fr) 1999-04-27 1999-04-27 Construction d'ADN pour l'expression spécifique tissulaire du facteur de coagulation sanguine
EP99107397.4 1999-04-29

Publications (2)

Publication Number Publication Date
CA2304376A1 true CA2304376A1 (fr) 2000-10-29
CA2304376C CA2304376C (fr) 2010-06-01

Family

ID=8237961

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2304376A Expired - Fee Related CA2304376C (fr) 1999-04-27 2000-04-28 Construction d'adn pour l'expression d'un facteur de coagulation du sang a specificite tissulaire

Country Status (11)

Country Link
US (1) US6884616B1 (fr)
EP (2) EP1048736A1 (fr)
JP (1) JP4373578B2 (fr)
KR (1) KR100681719B1 (fr)
AT (1) ATE339510T1 (fr)
AU (1) AU779437B2 (fr)
CA (1) CA2304376C (fr)
DE (1) DE60030621T2 (fr)
DK (1) DK1048726T3 (fr)
ES (1) ES2270758T3 (fr)
PT (1) PT1048726E (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425539B2 (en) 2004-03-19 2008-09-16 Baxter International Inc. Factor IXa for the treatment of bleeding disorders
WO2009045370A2 (fr) 2007-09-28 2009-04-09 Intrexon Corporation Constructions et bioréacteurs de commutation de gène théapeutique destinés à l'expression de molécules biothérapeutiques, et utilisation de ceux-ci
JP5997443B2 (ja) * 2008-05-16 2016-09-28 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 標的化凝固因子およびそれを使用する方法
WO2014066663A1 (fr) * 2012-10-24 2014-05-01 Platelet Targeted Therapeutics, Llc Traitement ciblant les plaquettes
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678282B1 (fr) 1991-06-28 1994-08-26 Commissariat Energie Atomique Sequences amplificateur et silenceur isolees du promoteur de la gpiib, et leurs applications.
EP0710288B1 (fr) * 1993-06-10 2006-04-05 Genetic Therapy, Inc. Vecteurs adenoviraux pour le traitement de l'hemophilie
US6066778A (en) * 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
FR2763959A1 (fr) * 1997-06-02 1998-12-04 Transgene Sa Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage

Also Published As

Publication number Publication date
EP1048736A1 (fr) 2000-11-02
US6884616B1 (en) 2005-04-26
JP4373578B2 (ja) 2009-11-25
ATE339510T1 (de) 2006-10-15
DE60030621T2 (de) 2007-09-27
AU779437B2 (en) 2005-01-27
EP1048735A1 (fr) 2000-11-02
KR100681719B1 (ko) 2007-02-15
ES2270758T3 (es) 2007-04-16
DK1048726T3 (da) 2006-11-20
PT1048726E (pt) 2006-12-29
JP2000333687A (ja) 2000-12-05
KR20010020795A (ko) 2001-03-15
AU3019500A (en) 2000-11-02
EP1048735B1 (fr) 2006-09-13
CA2304376C (fr) 2010-06-01
DE60030621D1 (de) 2006-10-26

Similar Documents

Publication Publication Date Title
Foster et al. The nucleotide sequence of the gene for human protein C.
AU3246300A (en) Polypeptides having galactose oxidase activity and nucleic acids encoding same
EP1460131A3 (fr) Préparation de facteurs de la coagulation sanguine recombinants en lignées cellulaires humaines
SG147430A1 (en) Nucleic acid constructs
WO1998046781A3 (fr) Nouveau systeme d'expression de transgene pour persistance accrue
EP2302063A3 (fr) mini-cellules entieres utilisees en tant que vecteurs pour le transfert d' ADN et la therapie genetique in vitro et in vivo
AU2001289457A1 (en) Methods and compositions employing a novel stearoyl-coa desaturase-hscd5
AU4777900A (en) Rnp originating in paramyxovirus
SG117416A1 (en) Fusion protein having enhanced in vivo activity oferythropoietin
PT99322B (pt) Processo para a preparacao de proteases
WO1999047678A3 (fr) Plasmides d'interferon alpha, systemes d'administration et procedes de fabrication desdits plasmides
DE69737996D1 (de) Methoden zur herstellung von nukleotidintegrasen
WO1998040498A3 (fr) Immunoadhesines et procedes de production et d'utilisation de ces dernieres
WO2003006612A3 (fr) Production de cellules de progeniteurs hematopoietiques transduites
ID29693A (id) Rangkaian-rangkaian nukleotida yang mengkode gen dapc dan proses untuk memproduksi l-lisin
CN101952423A (zh) 巴曲酶的突变核苷酸序列、突变的α因子分泌信号序列和使用其制备巴曲酶的方法
AU2002315010A1 (en) Nucleic acid constructs useful for glucose regulated production of human insulin in somatic cell lines
DK1048726T3 (da) Modificeret faktor VIII-cDNA
EP0336383A3 (fr) Lymphotoxine recombinante humaine
WO2003029457A1 (fr) Procede de production d'acide amine
ATE341630T1 (de) Verwendung von pankreatischer procarboxypeptidase b zur herstellung von insulin
AU7645400A (en) Polypeptides having glucanotransferase activity and nucleic acids encoding same
EP1262551A3 (fr) Gène codant pour la sorbitol déshydrogénase, ADN recombinant, et procédé de production de la sorbitol déshydrogénase
WO2000052133A3 (fr) Mutants de hansenula polymorpha et procede de preparation de proteines recombinantes
ES8704541A1 (es) Procedimiento para la preparacion de un vector con el sistema de expresion en trp

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130429